Company news

TrivarX Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MEB Signs Clinical Trial Agreement with MedBridge Healthcare

October 6, 2020

Request For FDA Breakthrough Device Designation Submitted

October 1, 2020

Patent Granted to Monitor Stress Conditions Using Heartrate

August 9, 2020

Entitlement Issue Results

July 9, 2020

Entitlement Offer Booklet

June 10, 2020

Placement and Fully Underwritten Entitlement Offer

June 9, 2020

Medibio submits FDA 510K Application to FDA

April 29, 2020

Final Compass Pilot Completed Successfully

April 8, 2020

Strategic Plan for FDA and CE Mark Approval

February 13, 2020

Company Update

December 8, 2019

Results of Annual General Meeting

November 22, 2019

Pause in Trading

November 21, 2019

Medibio Signs Agreement with PwC Australia for ilumen

October 23, 2019

MEB successfully completes first Ilumen pilot with Compass

October 20, 2019

Medibio Announces Results of Review of Partly Paid Shares

September 26, 2019

Fourth Pilot Agreement Signed with Compass Group for ilumen

August 30, 2019

Board Changes and Establishment of Advisory Board

August 29, 2019

MEB Signs Compass Group Australia to ilumen

July 29, 2019

MEB Partners with Corporate Wellness Solution Leader WellteQ

July 28, 2019

MEB Signs Second Compass Group PLC Pilot for ilumen

July 19, 2019

MEB Raises $4.02m via Placement and Fully Underwritten SPP

July 9, 2019

Suspension from Official Quotation

July 8, 2019

MEB Signs Compass Group to ilumen

June 30, 2019

Response to Appendix 4C Query

May 20, 2019

Regulatory and Commercialisation Strategy Update

April 29, 2019

Sponsored Research Agreement with Humanitas University

April 16, 2019

MEB Outsources Psychology Services in support of ilumen

March 13, 2019

Entitlement Issue Results and Shortfall Notification

March 12, 2019

Ilumen Successfully Completes First Commercial Program

March 6, 2019

Converting Note & Non-Renounceable Entitlement Offer

December 9, 2018

Exclusive Agreement Signed for ilumen Pilot Program

November 26, 2018

Response to ASX Appendix 4C Query

November 14, 2018

Medibio Provides Update on FDA Process

November 8, 2018

Medibio Appoints CEO and Managing Director

November 1, 2018

MEB Signs ilumen Contract with Large Australian Employer

October 23, 2018

Receipt of R&D Tax Incentive Refund

October 14, 2018

Medibio Releases Corporate Health Product, ilumen

October 3, 2018

Notice Received Under Section 249D of the Corporations Act

October 1, 2018

Executive Leadership Changes

September 20, 2018

Clinical Study Shows Improvement to Diagnostic Standard

September 5, 2018

Preliminary Final Report

August 29, 2018

Departure of Managing Director & Chief Executive Officer

August 28, 2018

Medibio Submits FDA De Novo Application

July 15, 2018

Medibio Receives TGA Approval

June 19, 2018

MEB Signs Global Contract with Jacobs Engineering

May 25, 2018

Medibio Announces Next Tranche of Corporate Health Contracts

May 9, 2018

Medibio Signs First Corporate Health Contract

May 8, 2018

Medibio Receives CE Certification

May 2, 2018

MEB signs binding term sheet to acquire Vital Conversations

March 4, 2018

Medibio Quarterly Update and Cash Flow Report

January 30, 2018

← Newer news releases · Older news releases →

Decks